Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506579 | 0.92 | KDM4E (0.58) | TSHRALDH1A1GAANPBWR1KMT2A | |
| SCHEMBL1546461 | 0.91 | TSHR (0.59) | TSHRALDH1A1GAANPBWR1KMT2A | |
| SCHEMBL3998128 | 0.88 | KDM4E (0.71) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL4006356 | 0.87 | ALDH1A1 (0.61) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL4001104 | 0.87 | KDM4E (0.69) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL3999221 | 0.86 | ALDH1A1 (0.62) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL4002823 | 0.79 | ALDH1A1 (0.62) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1547291 | 0.79 | ALDH1A1 (0.56) | TSHRALDH1A1KMT2AMEN1POLB | |
| SCHEMBL8260674 | 0.79 | TSHR (0.53) | TSHRALDH1A1GAANPBWR1KMT2A | |
| SCHEMBL11180002 | 0.78 | TSHR (0.73) | TSHRALDH1A1GAANPBWR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | TSHR 2239/4885ALDH1A1 3030/4885GAA 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.